Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Wels
Clinical trial register · Austria

Clinical Trials in Wels, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Austria and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1586 matching records held by the registry are in this view. Synced 14 Nov 2026, 03:18 UTC
1586
Studies in scope
all four open statuses
855
Recruiting now
open to new participants
341
Lead sponsors
across recruiting studies
Top sites
Vienna 1013 Graz 514 Linz 434 Innsbruck 396 Salzburg 292
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC7 AbbVie6 AstraZeneca6 Bristol-Myers Squibb4 Boehringer Ingelheim4 Gilead Sciences4 Regeneron Pharmaceuticals3 Alexion Pharmaceuticals, Inc.3 Merck Sharp & Dohme LLC3 Hoffmann-La Roche3 Medical University Innsbruck2 Olema Pharmaceuticals, Inc.2 Acerta Pharma BV2 Arbeitsgemeinschaft medikamentoese Tumortherapie2 Incyte Corporation2 GBG Forschungs GmbH2 Protagonist Therapeutics, Inc.1 Fundacio Clinic Barcelona1 Austrian Breast & Colorectal Cancer Study Group1 BeiGene1 Wuerzburg University Hospital1 Medical University of Vienna1 Amgen1 Geron Corporation1 Jazz Pharmaceuticals1 Show all 51
Site location
Vienna1013 Graz514 Linz434 Innsbruck396 Salzburg292 Sankt Pölten115 Wels90 Klagenfurt64 Feldkirch51 Krems35 Wiener Neustadt34 Leoben25 Rankweil25 Braunau am Inn17 Steyr12 Vöcklabruck7 Schwaz7 Mattersburg7 Sankt Veit an der Glan7 Kufstein6 Dornbirn6 Tulln5 Wein5 Mistelbach5 Eisenstadt4 Show all 99
All 99 locations
Target enrolment
to

Trials with a site in Wels

90 of 1586 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Austria
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Graz, Innsbruck, Vienna, Wels
2027-11-23
Recruiting
Takeda
Phase 3
324
Vienna, Innsbruck, Wels, Linz
2026-09-10
Recruiting
Incyte Corporation
Phase 3
426
Graz, Leoben, Linz, Vienna, Wels
2026-09-08
Recruiting
AstraZeneca
Phase 3
2,800
Feldkirch, Innsbruck, Linz, Sankt Pölten, Vienna, Wels, Wiener Neustadt
2026-09-01
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Linz, Salzburg, Vienna, Wels
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Linz, Salzburg, Vienna, Wels
2026-05-22
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Graz, Innsbruck, Linz, Salzburg, Vienna, Wels, Wiener Neustadt
2026-04-21
Recruiting
Austrian PBC Registry
NCT07598669Primary Biliary Cholangitis, Liver Cirrhosis, Portal Hypertension
Medical University of Vienna
Observational
500
Klagenfurt, Sankt Pölten, Salzburg, Vienna, Graz, Innsbruck, Linz, Wels
2026-03-18
Recruiting
SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors
NCT07341321mRNA Vaccination, Hepatocellular Carcinoma, Checkpoint Inhibitor
Medical University of Graz
Observational
200
Graz, Linz, Sankt Pölten, Sankt Veit an der Glan, Wels
2026-01-01
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Krems, Salzburg, Linz, Wels
2025-11-03
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
414
Krems, Wels
2025-09-13
Recruiting
Assessment of Coronary Artery Disease Before Transcatheter Aortic Valve Replacement: A Randomized, Multicenter, Non-Inferiority Trial
NCT07107568Aortic Valve Stenosis and Insufficiency, Coronary Artery Disease(CAD), Transcatheter Aortic Valve Replacement (TAVR)
Medical University Innsbruck
Not applicable
700
Innsbruck, Wels
2025-08-14
Recruiting
Hoffmann-La Roche
Observational
700
Krems, Linz, Vienna, Wels
2025-07-15
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Braunau am Inn, Graz, Vienna, Wels
2025-07-02
Active, closed
AbbVie
Phase 3
573
Graz, Linz, Wels, Salzburg, Vienna
2025-06-17
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Linz, Salzburg, Vienna, Wels
2025-06-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Linz, Wels, Salzburg
2025-05-13
Recruiting
Hoffmann-La Roche
Phase 3
425
Linz, Wels
2025-05-12
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Graz, Wels, Linz, Vienna
2025-04-24
Recruiting
Bristol-Myers Squibb
Phase 3
530
Graz, Wels, Linz, Rankweil
2025-02-25
Recruiting
Fast Discharge After Acute Myocardial Infarction Discharge MI
NCT06744322Acute Myocardial Infarction (AMI)
Medical University Innsbruck
Not applicable
2,070
Wiener Neustadt, Schwarzach im Pongau, Salzburg, Graz, Innsbruck, Wels, Feldkirch
2024-12-01
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Graz, Linz, Vienna, Wels
2024-11-12
Recruiting
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
NCT06678919Metastatic Colorectal Cancer (mCRC)
Arbeitsgemeinschaft medikamentoese Tumortherapie
Observational
500
Linz, Rankweil, Salzburg, Steyr, Wels, Zams
2024-10-31
Recruiting
argenx
Phase 3
69
Linz, Wels
2024-10-18
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Graz, Linz, Vienna, Wels
2024-10-14
Recruiting
Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
NCT06446882HER2-positive Breast Cancer, Early-stage Breast Cancer
Fundacio Clinic Barcelona
Not applicable
304
Graz, Leoben, Linz, Salzburg, Sankt Pölten, Vienna, Wels
2024-10-11
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Krems, Wels, Vienna
2024-10-07
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Krems, Salzburg, Vienna, Wels
2024-09-26
Recruiting
AbbVie
Phase 2
590
Graz, Innsbruck, Linz, Wels, Salzburg, Vienna
2024-09-04
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Innsbruck, Linz, Vienna, Wels
2024-08-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Innsbruck, Linz, Wels, Salzburg, Vienna
2024-06-24
Active, closed
Celgene
Phase 3
850
Wels, Linz, Vienna
2024-06-19
Active, closed
The Lymphoma Academic Research Organisation
Phase 3
790
Graz, Krems, Leoben, Linz, Salzburg, Sankt Pölten, Vienna, Wels
2024-06-07
Recruiting
AstraZeneca
Phase 3
675
Innsbruck, Krems, Linz, Rankweil, Vienna, Wels
2024-04-11
Active, closed
University of Heidelberg Medical Center
Phase 3
411
Krems, Linz, Salzburg, Vienna, Wels
2024-04-05
Recruiting
Italfarmaco
Phase 3
220
Wiener Neustadt, Vienna, Linz, Wels
2024-03-26
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,350
Graz, Innsbruck, Klagenfurt, Sankt Pölten, Wels
2024-03-13
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,182
Graz, Innsbruck, Vienna, Wels
2024-01-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Graz, Linz, Wels
2023-12-31
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
Linz, Vienna, Wels
2023-12-28
Recruiting
Regeneron Pharmaceuticals
Phase 3
904
Leoben, Linz, Graz, Vienna, Wels
2023-12-13
Active, closed
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
257
Linz, Vienna, Wels, Wiener Neustadt, Zams
2023-12-05
Recruiting
Amgen
Phase 3
750
Graz, Klagenfurt, Krems, Oberwart, Salzburg, Vienna, Wels
2023-11-16
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Wels, Wiener Neustadt
2023-11-16
Recruiting
Charite University, Berlin, Germany
Not applicable
3,595
Feldkirch, Graz, Innsbruck, Klagenfurt, Linz, Salzburg, Sankt Pölten, Wels
2023-11-16
Active, closed
Regeneron Pharmaceuticals
Phase 3
733
Sankt Pölten, Graz, Leoben, Innsbruck, Linz, Vienna, Wels
2023-11-14
Active, closed
AstraZeneca
Phase 3
895
Linz, Wels
2023-10-24
Active, closed
AstraZeneca
Phase 3
5,511
Graz, Innsbruck, Linz, Salzburg, Sankt Veit an der Glan, Steyr, Vienna, Wels
2023-10-05
Recruiting
Gilead Sciences
Phase 3
402
Hall in Tirol, Vienna, Wels
2023-09-07
Recruiting
Servier Affaires Médicales
Phase 3
245
Vienna, Wels
2023-06-14
Active, closed
AbbVie
Observational
1,019
Sankt Pölten, Vienna, Graz, Innsbruck, Wels
2023-06-09
Active, closed
Gilead Sciences
Phase 3
654
Innsbruck, Salzburg, Vienna, Wels
2023-05-08
Recruiting
AstraZeneca
Phase 3
4,300
Graz, Kufstein, Ried, Sankt Veit an der Glan, Vienna, Wein, Wels
2023-03-31
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Klagenfurt, Wels
2023-02-15
Active, closed
Celcuity Inc
Phase 3
701
Graz, Innsbruck, Linz, Salzburg, Sankt Pölten, Vienna, Wels
2022-12-08
Active, closed
Novartis Pharmaceuticals
Phase 2
95
Feldkirch, Wels
2022-12-06
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
260
Innsbruck, Wels
2022-11-21
Recruiting
Pfizer
Phase 3
1,060
Sankt Pölten, Vienna, Graz, Linz, Wels, Rankweil, Salzburg
2022-11-10
Active, closed
AstraZeneca
Phase 3
368
Vienna, Wels
2022-11-10
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Wels, Salzburg, Vienna, Wiener Neustadt
2022-10-24
Recruiting
GBG Forschungs GmbH
Observational
400
Innsbruck, Wels, Graz, Linz, Salzburg, Vienna
2022-10-12
Active, closed
Gilead Sciences
Phase 3
1,021
Linz, Vienna, Wels
2022-10-12
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Salzburg, Vienna, Wels
2022-09-19
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
DrugsAbraxane·Nab-paclitaxel·Gemcitabine
Panbela Therapeutics, Inc.
Phase 2/3
600
Klagenfurt, Sankt Pölten, Linz, Steyr, Wels, Rankweil, Salzburg, Wein
2022-08-08
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Salzburg, Vienna, Wels
2022-07-22
Active, closed
Incyte Corporation
Phase 1/2
53
Sankt Pölten, Wels, Salzburg
2022-07-19
Active, closed
Daiichi Sankyo
Phase 3
586
Feldkirch, Innsbruck, Klagenfurt, Vienna, Wels
2022-07-08
Active, closed
Protagonist Therapeutics, Inc.
Phase 3
293
Graz, Linz, Vienna, Wels
2022-04-11
Recruiting
AbbVie
Phase 3
768
Vienna, Innsbruck, Linz, Wels, Feldkirch, Salzburg
2022-03-25
Recruiting
The "Global Paradise System" Registry
NCT05027685Hypertension
ReCor Medical, Inc.
Observational
3,000
Vienna, Wels
2022-01-13
Active, closed
Geron Corporation
Phase 3
327
Wein, Linz, Wels
2021-04-12
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Graz, Saint Stefan, Salzburg, Vienna, Wels
2021-04-01
Active, closed
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565HER2-negative Breast Cancer, Triple Negative Breast Cancer
DrugsXeloda·Sacituzumab Govitecan·Paraplatin·Capecitabine
GBG Forschungs GmbH
Phase 3
1,332
Graz, Innsbruck, Linz, Salzburg, Sankt Pölten, Vienna, Vöcklabruck, Wels
2020-10-28
Active, closed
Acerta Pharma BV
Phase 3
611
Linz, Wels
2020-10-08
Active, closed
AbbVie
Phase 3
531
Vienna, Linz, Wels, Salzburg
2020-09-10
Active, closed
AbbVie
Phase 3
330
Sankt Pölten, Vienna, Graz, Linz, Wels
2020-08-31
Active, closed
Institut für Pharmakologie und Präventive Medizin
Observational
500
Innsbruck, Linz, Salzburg, Wels
2019-12-12
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Graz, Linz, Sankt Pölten, Vienna, Wels
2019-08-09
Active, closed
Bristol-Myers Squibb
Phase 3
437
Graz, Vienna, Wels
2019-06-21
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Klagenfurt, Vienna, Linz, Salzburg, Sankt Pölten, Wels
2019-03-28
Active, closed
Austrian Breast & Colorectal Cancer Study Group
Not applicable
92
Salzburg, Graz, Kufstein, Braunau am Inn, Linz, Steyr, Wels
2019-02-14
Active, closed
Ipsen
Observational
224
Leoben, Linz, Salzburg, Vöcklabruck, Wels
2018-09-24
Active, closed
Wuerzburg University Hospital
Phase 3
576
Krems, Sankt Pölten, Graz, Innsbruck, Linz, Wels, Rankweil, Salzburg
2018-08-28
Active, closed
University Hospital, Basel, Switzerland
Not applicable
1,500
Dornbirn, Feldkirch, Innsbruck, Linz, Salzburg, Vienna, Wels
2018-08-07
Active, closed
Gilead Sciences
Phase 3
340
Wels
2017-12-12
Active, closed
BeiGene
Phase 3
590
Innsbruck, Linz, Salzburg, Wels
2017-10-31
Recruiting
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
NCT04204837Squamous Cell Carcinoma of the Skin
DrugsRelatlimab·Nivolumab
Salzburger Landeskliniken
Phase 2
61
Graz, Innsbruck, Klagenfurt, Salzburg, Sankt Pölten, Vienna, Wels
2017-03-06
Active, closed
Acerta Pharma BV
Phase 3
310
Linz, Salzburg, Vienna, Wels
2017-02-02
Recruiting
Fosfomycin I.v. for Treatment of Severely Infected Patients
NCT02979951Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
Infectopharm Arzneimittel GmbH
Observational
1,000
Hall in Tirol, Reutte, Vienna, Wels
2016-12
Recruiting
Metastatic Breast Cancer in Austria
NCT03870620Breast Cancer, Breast Carcinoma, Breast Tumor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Observational
5,000
Salzburg, Vienna, Graz, Innsbruck, Kufstein, Linz, Steyr, Wels
2015-06-15
Rows per page Showing 1–90 of 90
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Austrian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-austria/city/wels

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Austria and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,586 studies in total at the last sync on 14 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 90 of those studies with a site in Wels.

How many clinical trials are recruiting in Wels?

48 of the 90 studies on this page are recruiting new participants as of the 14 Nov 2026, 03:18 UTC sync. A further 1 have not yet opened recruitment, 41 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Wels), 90 studies
PhaseStudiesRecruitingShare
Phase 3643271.1%
Observational12813.3%
Not applicable646.7%
Phase 2636.7%
Phase 1/2101.1%
Phase 2/3111.1%

Most active sponsors

Lead sponsors with the most studies (Wels)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC74
AbbVie62
AstraZeneca63
Boehringer Ingelheim42
Bristol-Myers Squibb43
Gilead Sciences41
Alexion Pharmaceuticals, Inc.30
Hoffmann-La Roche33
Merck Sharp & Dohme LLC33
Regeneron Pharmaceuticals32
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.